Related Experiment Video
Updated: Jun 2, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Molecular diagnostics of lung carcinomas
1Department of Pathology, University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, PA 15213, USA. dacics@upmc.edu
Archives of Pathology & Laboratory Medicine
|April 30, 2011
Summary
Identifying specific epidermal growth factor receptor (EGFR) mutations in lung carcinoma is crucial for predicting response to targeted therapies like EGFR-tyrosine kinase inhibitors (TKIs). Standardized molecular testing is needed for personalized lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted therapies for lung carcinoma are advancing rapidly.
- Accurate histologic classification and biomarker testing are essential for treatment selection.
- Molecular testing adds complexity to analyzing limited tumor tissue samples.
Purpose of the Study:
- To review key lung carcinoma biomarkers predicting treatment response.
- To discuss the implementation of routine molecular testing in clinical practice.
Main Methods:
- Literature review of PubMed-indexed articles.
- Inclusion of peer-reviewed original articles.
- Incorporation of author's clinical experience.
Main Results:
- Histologic, clinical, and mutational profiles predict response to EGFR-TKIs and targeted therapies.
- Activating EGFR mutations are the strongest predictors of EGFR-TKI response.
- Current molecular profiling lacks standardization and validation in clinical practice.
Conclusions:
- Mutational profiling is vital for identifying non-small cell lung carcinoma patients who will benefit from targeted therapies.
- Standardized molecular testing is necessary for routine clinical application.
- Future lung cancer treatment will rely on molecular subtyping for personalized care.